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However, cats also produce notable amounts of a C‐3 epimer of 25(OH)D (3‐epi). 
Hypothesis/Objectives Determine if vitamin D status, estimated by 25(OH)D3 alone or combined with 
3‐epi (summation vitD), is lower in cats with cardiomyopathy (CM) compared to clinically normal (N) cats 
and if indicators of disease severity are associated with vitamin D status. 
Animals Privately owned cats, 44 with CM and 56 N. 
Methods Cross‐sectional observational study using clinical and echocardiographic findings, diet history, 
and serum 25(OH)D3 and 3‐epi measurements. 
Results Cat age was negatively related to vitamin D status. Summation vitD was lower in CM cats 
(median = 47.1 ng/mL) compared to N cats (median = 58.65 ng/mL) both before (P = .03) and after (P = 
.04) accounting for age. However, 25(OH)D3 became nonsignificant between CM and N cats after age 
was included. Summation vitD was related positively to survival time and fractional shortening (FS), but 
negatively to left atrial enlargement (LAE) severity, both before and after accounting for age. For 
25(OH)D3 alone, only survival time and FS remained significant after including age. 
Conclusions and Clinical Importance We report 25(OH)D3 and 3‐epi concentrations in CM and N cats. 
Age had an important (negative) relationship to vitamin D status. After accounting for age, summation 
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to LAE severity. 
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Abstract
Background: Low vitamin D concentrations have been associated with advanced
heart disease and poorer outcomes in people and dogs. Vitamin D status typically is
assessed by serum 25(OH)D concentration. However, cats also produce notable
amounts of a C-3 epimer of 25(OH)D (3-epi).
Hypothesis/Objectives: Determine if vitamin D status, estimated by 25(OH)D3 alone
or combined with 3-epi (summation vitD), is lower in cats with cardiomyopathy (CM)
compared to clinically normal (N) cats and if indicators of disease severity are associ-
ated with vitamin D status.
Animals: Privately owned cats, 44 with CM and 56 N.
Methods: Cross-sectional observational study using clinical and echocardiographic
findings, diet history, and serum 25(OH)D3 and 3-epi measurements.
Results: Cat age was negatively related to vitamin D status. Summation vitD was lower
in CM cats (median = 47.1 ng/mL) compared to N cats (median = 58.65 ng/mL) both
before (P = .03) and after (P = .04) accounting for age. However, 25(OH)D3 became non-
significant between CM and N cats after age was included. Summation vitD was related
positively to survival time and fractional shortening (FS), but negatively to left atrial
enlargement (LAE) severity, both before and after accounting for age. For 25(OH)D3
alone, only survival time and FS remained significant after including age.
Conclusions and Clinical Importance: We report 25(OH)D3 and 3-epi concentrations
in CM and N cats. Age had an important (negative) relationship to vitamin D status.
After accounting for age, summation vitD was lower in CM cats. Vitamin D status
was related positively to survival time and FS, but negatively to LAE severity.
K E YWORD S
25(OH)D, 3-epimer, feline, myocardial disease
1 | INTRODUCTION
Decreased concentrations of vitamin D (as assessed by serum 25(OH)
D concentration) have been observed in people with systemic hyper-
tension and other cardiovascular (CV) conditions that often lead to
congestive heart failure (CHF). Low vitamin D status has been
Abbreviations: 1, 25[OH]2D3, calcitriol; 25(OH)D, calcidiol, 25-hydroxyvitamin D3 (± D2)
3-epi, C-3 epimer of 25(OH)D, 3-epi-25(OH)D3; CHF, congestive heart failure; CM,
cardiomyopathy; CV, cardiovascular; DMVD, degenerative (myxomatous) mitral valve
disease; Echo, echocardiography; FS, fractional shortening; HCM, hypertrophic
cardiomyopathy; HOCM, hypertrophic obstructive cardiomyopathy; ISU, Iowa State
University; LAE, left atrial enlargement; LC/MS/MS, liquid chromatography-tandem mass
spectrometry; LV, left ventricular; N, clinically normal; RCM, restrictive cardiomyopathy;
Summation vitD, sum of 25(OH)D3 and 3-epi concentrations; UHPLC, ultra-high pressure
liquid chromatography; vitamin D3, cholecalciferol.
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associated with disease progression and poorer prognosis in people
with CV disease and CHF, including those with diastolic dysfunction
and preserved ejection fraction.1-3 Vitamin D is thought to have a pro-
tective effect on the CV system through regulatory influences on
blood pressure, as well as on cardiac, endothelial, and smooth muscle
cell function.1 Many studies report 25(OH)D measurement without
specifying whether 25(OH)D3 only has been measured, or both
25(OH)D3 and 25(OH)D2 (ie, total 25(OH)D or 25(OH)D2/3). As a
point of clarification, we use “25(OH)D” in reference to reports using
the same general term; otherwise, we employ the more specific
terminology.
Two small studies in dogs with degenerative (myxomatous) mitral
valve disease (DMVD) or dilated cardiomyopathy (CM) showed lower
serum 25(OH)D concentrations in those with heart failure (or
advanced preclinical disease) compared to normal dogs.4,5 Associa-
tions between low vitamin D status and more advanced cardiac remo-
deling, worse function, and negative clinical outcome were noted. It is
not known whether vitamin D status is lower in cats with CM com-
pared to normal cats, and if so, whether an association exists between
vitamin D status and disease severity or outcome.
Although the most biologically active form of vitamin D is cal-
citriol (1, 25(OH)2D3), its immediate precursor, 25(OH)D (or calcidiol),
is more stable in the circulation. Therefore, serum 25(OH)D concen-
tration typically has been used to assess vitamin D status, especially in
people and dogs. Dietary precursors of 25(OH)D2/3 are cholecalciferol
(vitamin D3) from animal food sources, and ergocalciferol (vitamin D2)
from plant sources; in cats and dogs, contributions from vitamin D2
are minimal. These species rely on dietary intake because they cannot
synthesize vitamin D3 within the skin after ultraviolet light exposure.
6
An additional consideration regarding vitamin D status in cats is
the formation of a C-3 epimer of 25(OH)D3 (3-epi-25(OH)D3 or 3-
epi). This metabolite is known to occur in people, cats, rats and,
recently, dogs.6-9 Circulating concentrations of 3-epi, compared to 25
(OH)D3, appear to be much higher in cats than in people and dogs.
8,9
Epimeric forms of vitamin D are thought to have at least some biologi-
cal activity, although how much is unclear.
We hypothesized that vitamin D status would be lower in cats
with CM compared to clinically normal (N) cats. The main purpose of
our study was to determine if vitamin D status, as assessed by serum
25(OH)D2/3 or the summation of 3-epi and 25(OH)D3 concentrations
(summation vitD), is lower in cats with spontaneously occurring CM
compared to clinically healthy cats. We also sought to identify
whether certain clinical variables or indicators of disease severity are
associated with vitamin D status.
2 | MATERIAL AND METHODS
Our study was a cross-sectional observational study. The CM group
was recruited from privately owned cats presented for veterinary care
at the Veterinary Medical Centers of Iowa State University (ISU) and
Tufts University between November 2016 and April 2018. Cats were
entered into the CM group based on echocardiographic evidence for
hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive car-
diomyopathy (HOCM), restrictive cardiomyopathy (RCM), or other
forms of CM, and left atrial enlargement (LAE), as an indication of at
least moderate disease severity. Cats were excluded if they had clini-
cal, client-reported, or prior medical record evidence for serious sys-
temic disease at enrollment, including severe hypertension
(>180 mm Hg, systolic), hyperthyroidism, severe chronic kidney dis-
ease, active inflammatory bowel disease, systemic neoplasia, or wide-
spread infectious or inflammatory disease. The N group was recruited
at ISU during approximately the same time period and was composed
of cats owned by students, staff, and local community residents. As an
entry criterion, all cats were being fed commercial cat food (not a
homemade diet) as the primary diet. Owners completed detailed diet
and health history (see Supporting Information) and informed consent
forms. The study was approved by the animal care and use commit-
tees at both universities.
Clinical data collected included signalment, body weight (kg), body
condition (1-9), and muscle condition (1-4; https://www.wsava.org/
Guidelines/Global-Nutrition-Guidelines) scores, CV examination find-
ings, indirect systolic blood pressure measurement (mm Hg, Doppler
method, average of at least 3-5 readings) and echocardiography (echo;
2-D, M-mode, color flow, and spectral Doppler). Echo studies were
performed by a board-certified cardiologist or a cardiology resident
under the direct supervision of a board-certified cardiologist. Cats
with CM were classified according to the American College of Veteri-
nary Internal Medicine (ACVIM) heart disease staging system pro-
posed for cats, which is similar to that used for dogs with DMVD.10
Stage B2 cats had evidence for CM and atrial enlargement, but had
not developed CHF. Stage C cats had signs of CHF either at presenta-
tion (stage C-active CHF) or in the past, which resolved with heart
failure treatment (stage C-compensated). A venous blood sample (1-
2 mL) also was obtained for 25(OH)D2/3 and 3-epi measurement;
serum was separated and then immediately frozen and stored at
−80C until analyzed. Screening serum biochemistry and thyroid tests
were not performed in all cats at enrollment because of financial con-
straints. For most cats, however, where that information was not oth-
erwise available, we measured creatinine, blood urea nitrogen,
electrolyte, and T4 concentrations. Follow-up to determine survival
status at study closure (February 1, 2019) was by phone or email con-
tact with cat owners or referring veterinarians.
Assays for 25(OH)D3, 25(OH)D2, and 3-epi were performed by a
commercial laboratory (Heartland Assays, Ames, Iowa) that is Vitamin
D External Quality Assessment Scheme (DEQAS) certified using liquid
chromatography-tandem mass spectrometry (LC/MS/MS; Agilent
6460 MS/MS with ESI source, assayed in positive mode; Aglient
Technologies, Santa Clara, California) according to previously
described methods.11-13 Briefly, serum samples along with standard
curve and controls were protein precipitated using 0.2 M zinc sulfate
solution, vortexed, followed by methanol addition and d3-25(OH)D2/
d3-25(OH)D3 internal standards. All samples and controls were
vortexed followed by hexane addition then capped, vortexed, and
centrifuged. Organic layer was transferred and dried. All standards,
controls, and samples then were reconstituted with LC/MS grade
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methanol and water (both containing 0.1% formic acid), and loaded
onto the autosampler for analysis. Analyte separation was achieved
using ultra-high pressure liquid chromatography (UHPLC) with a pen-
tyl fluoro phenyl (PFP) column (Agilent 1290 infinity UHPLC and
Poroshell Pentyl fluoro phenyl [PFP 2.1 × 100 mm 2.7 μm] column;
Aglient Technologies) to selectively separate 3-epi-25(OH)D3 from
the 25(OH)D3. Assay accuracy was determined to be >95%, based on
National Institute of Standards and Technology-certified standard
assessment for 25(OH)D2, 25(OH)D3, and 3-epi-25(OH)D3.
12,13
Diet histories provided by cat owners, along with more specific
details obtained as necessary by follow-up owner contact, were used
to estimate vitamin D intake from commercial cat foods eaten by indi-
vidual cats. Intake from treats was minimal for all cats, and thus vita-
min D intake from treats or table food was not included.
Manufacturers of specific commercial diets being fed were contacted
for data on vitamin D content in those diets. Estimated daily vitamin
D intake (IU cholecalciferol/kg body weight) was calculated from the
estimated daily amount of each specific diet eaten by individual cats,
in conjunction with the manufacturer's reported vitamin D content for
the diet.
Clinical variables included for analysis were: age, sex, body
weight, body condition score, muscle condition score, diagnosis cate-
gory (N, HCM, HOCM, or other CM), heart disease category (N = none,
or ACVIM stage B2, stage C-compensated, or stage C-active CHF),
number of days since onset of CHF (or 0, for N and stage B2 CM),
presence or absence of pleural effusion at enrollment, presence or
absence of an arrhythmia, survival time (days from enrollment to
death or study end date, whichever occurred first), presence or
absence of an arterial thromboembolic event (historical or during
study period), and estimated daily vitamin D intake (IU/kg). Echocar-
diographic findings analyzed were: LAE severity category (right par-
asternal long-axis view, systole: none, LA diameter < 17 mm; mild, 17-
18 mm; moderate, 19-22 mm; or severe, >22 mm), sum of diastolic
interventricular septal and left ventricular (LV) free wall thicknesses
(as estimate of LV hypertrophy), LV fractional shortening (FS), and
end-diastolic LV internal diameter. The latter 3 variables were
obtained from the right parasternal short-axis view. To help further
define the influence of age on relationships between vitamin D status
and certain clinical variables, we also categorized cats into 3 age
groups (1: ≤5 years old, n = 26; 2:6-9 years old, n = 22; and 3:
≥10 years old, n = 52).
Statistical tests were performed using R, an open-source software
(R Core Team [2018], R Foundation for Statistical Computing, Vienna,
Austria, https://www.R-project.org/). One-way analysis of variance
(for continuous factors) and Fisher's exact test (for categorical factors)
were used to compare the CM and N populations. Pearson correlation
tested for relationship between serum concentrations of 25(OH)D3
and 3-epi. Multiple linear regression modeling to include all potential
explanatory variables was explored but multicollinearity among vari-
ables confounded this approach. Therefore, backward selection was
performed to eliminate the full model. In addition, linear regressions
were conducted separately on each of the clinical variables to test for
their relationships with 25(OH)D3, 3-epi alone, or summation vitD
concentrations individually. To account for the effect of age, this
TABLE 1 Study population characteristics of cats with cardiomyopathy and clinically normal controls
Cardiomyopathy cats (n = 44) Clinically normal cats (n = 56)
Age (y), median (range) 10.5 (0.6-17.5) 9.25 (1-23)
Sex
Male 36 neutered, 1 intact 37 neutered
Female 7 spayed 17 spayed, 2 intact
Body weight (kg), median (range) 4.9 (2.9-8.6) 5.1 (2.3-7.7)
Body condition score 5 (3-8) 6 (2-9)
Muscle condition score 4 (1-4) 4 (1-4)
Breeds
Domestic shorthair/longhair 37 50
Other (purebred) 1 each: Maine Coon, Norwegian Forest,
Persian, Ragdoll, Savanah, Siamese, and
Sphynx cats
2 Bengals and 1 each: Himalayan, Persian,





Other (includes 6 RCM, 6 “unspecified”
CM, and 3 DCM)
15 0
Abbreviations: CM, cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HOCM, hypertrophic obstructive cardiomyopa-
thy; N, normal; RCM, restrictive cardiomyopathy.
*P < .001. Other comparisons between CM and N groups showed no significant differences.
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important factor was included together with each clinical variable in
further regression analysis. Model diagnostics were conducted to con-
firm assumptions of linear regression. The Wilcoxon Rank Sum test
was used to compare estimated dietary vitamin D intake in CM and N
cats, because of skewness of data distribution. Possible relationships
between vitamin D intake and 25(OH)D3, 3-epi, or summation vitD
were assessed by Pearson correlation. P values <.05 were considered
significant.
3 | RESULTS
Forty-four CM cats were enrolled (29 at ISU and 15 at Tufts). Thirty-
eight of 44 CM cats (86%) had a history of CHF. The majority (68%)
of these had active signs of congestion at presentation, although
some were well compensated on heart failure treatment. We enrolled
56 N cats during the same time period, 44 of which were sex- and
age-matched (±6 months) to the CM cats. Analyses reported here
included the 44 CM cats and 56 N cats. Comparison of study group
characteristics identified no significant differences between CM and
N groups, except for diagnosis category (Table 1).
Serum concentrations of 25(OH)D3 and 3-epi correlated posi-
tively with each other for all cats combined (Figure 1; correlation coef-
ficient, 0.35; P < .001). Results were similar when CM (correlation
coefficient, 0.32; P = .04) and N (correlation coefficient, 0.33; P = .01)
cat groups were analyzed separately. We also evaluated the ratio of
3-epi to summation vitD. No difference in mean ratio was found
F IGURE 1 Scatterplot of serum 25(OH)D3 and 3-epi-25(OH)D3
concentrations, color-grouped by CM status. Serum 25(OH)D3 and 3-
epi-25(OH)D3 concentrations were positively correlated with each
other (results for all CM and normal cats together shown); correlation
coefficient = 0.35; P < .001. CM, cardiomyopathy
TABLE 2 Summary statistics for selected continuous variables
Variable Number of observations Mean Min. 25th percentile Median 75th percentile Max.
25(OH)D3 (ng/ml) (All cats) 100 41.04 14.7 29 38.8 49.83 85.6
CM cats 44 37.45 14.7 27.25 35.4 48.73 67.3
N cats 56 43.86 18.3 31.75 42.75 50.25 85.6
3-epi (ng/mL) (All cats) 100 12.64 3.1 7.85 11.55 15.98 30
CM cats 44 11.57 3.7 7.43 10.7 14.63 28.7
N cats 56 13.48 3.1 8.25 12.1 18.38 30
Summation vitD (ng/mL) (All cats) 100 53.68 19.8 38.78 54.3 64.18 103.4
CM cats 44 49.02 19.8 37.9 47.1 59.78 93
N cats 56 57.34 24.9 40.58 58.65 65.53 103.4
3-epi as % of (summation vitD) (All cats) 100 23.88 9.6 17.33 22.82 30 47.4
CM cats 44 24.28 9.6 18.64 24.28 30.33 47.4
N cats 56 23.57 10 17.13 22.7 29.77 41
Survivala (d) (All cats) 90 369.52 4 131.25 346.5 616 831
CM cats 42 252.95 4 50.5 197 376.5 831
N cats 48 471.52 54 339 459 669 823
LV fractional shortening (%) (All cats) 99 47.68 11.8 42.45 49.6 55.75 70
CM cats 43 41.23 11.8 26.85 44.2 53.3 70
N cats 56 52.64 37.9 46.78 52.45 57.93 70
Estimated vitamin D intake (IU/kg) (All cats) 74 25.11 4.51 12.34 18.73 29.71 96.9
CM cats 33 32.08 5.45 18.18 22.5 35.85 96.9
N cats 41 19.5 4.51 10.5 15.5 24.53 61.7
Abbreviations: 3-epi, 3-epi-25(OH)D3; CM, cardiomyopathy; LV, left ventricular; N, normal; Summation vitD, sum of 25(OH)D3 and 3-epi concentrations.
aSurvival days were taken as right-censored at study end date to include as many data points as possible.
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between CM cats and N cats. Table 2 contains summary statistics for
these vitamin D measures. The concentration of 25(OH)D2 was below
detection limits (<1.5 ng/mL) in all cats, and thus no analysis was
performed.
To determine multiple linear regression models for 25(OH)D3 and
summation vitD, we started with full models including all clinical vari-
ables. Because of the multicollinearity issue, and based upon the par-
simony principle, we decreased the full models with backward
elimination. For 25(OH)D3, only age, survival time, and FS remained;
the latter 2 predictors were positively correlated (correlation coeffi-
cient 0.411). Therefore, from a practical standpoint, survival time was
removed from the model, because this information could be more dif-
ficult to obtain than echo assessment of FS. The resulting model was:
25(OH)D3 = 35.77 − 0.98 × age + 0.31 × FS, with R2 = 0.15. Hence,
on average and with other conditions fixed, a 1 year increase in age is
associated with 0.98 ng/mL decrease in 25(OH)D3 (P = .002) and a
1% increase in FS is associated with 0.31 ng/mL increase in 25(OH)
D3 (P = .009).
Similarly, for summation vitD, backward selection decreased the
model to factors age, muscle score, survival time, and FS; the latter 3
have P values between .05 and .1. After removing survival time for
the same practical reason and backward selecting the model, we
attained summation vitD = 47.86 − 1.2 × age + 0.37 × FS, with
R2 = 0.16. Thus, on average, each 1 year increase in age is associated
with 1.2 ng/mL decrease in summation vitD (P = .001), whereas a 1%
increase in FS is associated with 0.37 ng/mL increase in summation
vitD (P = .009).
In addition to modeling vitamin D measurements with clinical pre-
dictors combined, their associations with each individual predictor,
CM status (CM versus N), age, sex, and the other clinical variables,
were assessed. Significant results are listed in Table 3, including model
coefficients (β), P values, and R2 values. Age (as a continuous variable)
was negatively related to 25(OH)D3. After accounting for age, the dif-
ference in 25(OH)D3 between CM and N groups became nonsignifi-
cant (Figure 2). No relationship was found between sex and 25(OH)
D3. For 3-epi, CM status, age, and sex were nonsignificant. For sum-
mation vitD, as with 25(OH)D3, age was a significant factor (P = .001).
In contrast to 25(OH)D3 alone, summation vitD was significantly dif-
ferent between CM and N cats even after including age in the model
(P = .04; Figure 3).









Variable Age Variable Age
CM versus N (N: baseline) β −6.406 −5.624 −0.947 −8.321 −7.359 −1.164
P .04 .06 .003 .03 .04 .002
R2 0.042 0.128 0.049 0.140
Age β −0.996 — — −1.228 — —
P .002 .001
R2 0.096 — 0.102 —
Survival time β 0.022 0.017 −0.844 0.027 0.019 −1.096
P .001 .02 .01 .001 .02 .009
R2 0.117 0.175 0.115 0.183
Left atrial enlargement β −2.844 −2.442 −0.916 −3.921 −3.431 −1.116
P .04 .07 .004 .02 .03 .003
R2 0.043 0.123 0.058 0.140
Fractional shortening β 0.307 0.308 −0.977 0.364 0.365 −1.202
P .01 .009 .002 .01 .009 .001
R2 0.063 0.155 0.062 0.159
Diagnosis category: other CMa versus N (N: baseline) β −8.067 −6.493 −0.938 −10.914 −8.990 −1.146
P .08 .14 .004 .05 .09 .003
R2 0.048 0.128 0.058 0.142
Heart failure severityb β −2.221 −1.855 −0.945 −3.127 −2.679 −1.155
P .07 .11 .003 .03 .05 .002
R2 0.034 0.119 0.047 0.136
Abbreviations: CM, cardiomyopathy; N, normal; Summation vitD, sum of 25(OH)D3 and 3-epi concentrations.
aSee Table 1 and text for further details.
bSee text for further details.
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Positive associations were seen between summation vitD and the
variables survival days and FS, and negative association was seen with
LAE severity, both before and after accounting for age. The diagnosis
category of other CM showed a significantly smaller mean summation
vitD concentration compared to N cats before accounting for age but,
with age in the model, the relationship was nonsignificant. Further
analysis using the filter of previously defined age groups indicated
that older cats (age group 3) with other CM had lower summation
vitD, compared to N cats (P = .04). Heart failure severity had a nega-
tive relationship with summation vitD before age was included in the
model (P = .03); but, this difference became only borderline after
accounting for age (P = .05). When the age group filter was applied, a
negative relationship between heart failure severity and summation
vitD was identified in the young cat group (1). Only 8/24 cats in this
age group had decompensated CHF, but summation vitD was
extremely low (20.6 ng/mL) in 1 of them. When this outlier was
excluded from analysis, heart failure was no longer a significant vari-
able for group 1 cats. For 25(OH)D3 by itself, significant positive rela-
tionships were found with survival days and FS, and a negative
relationship was found with LAE severity. However, after accounting
for the effect of age, only survival time and FS remained significant.
Diastolic LV internal diameter was positively associated with age, but
not with 25(OH)D3 or summation vitD after age was included in the
model.
We intended to exclude cats with more than minor azotemia from
our study but we discovered after enrollment that a small number of
geriatric cats with emergency presentations for CHF actually had
more marked azotemia. Therefore, we included azotemia status in the
analysis using the categorization criteria: none, serum creatinine con-
centration (creat) < 2.1 mg/dL or blood urea nitrogen concentration
(BUN) < 29 mg/dL; mild, creat 2.2 to 2.9 mg/dL or BUN 30 to 40 mg/
dL; moderate, creat 3 to 4 mg/dL or BUN 41 to 50 mg/dL; and severe,
creat >4 mg/dL or BUN >51 mg/dL. Azotemia status was positively
associated with age, but not with 25(OH)D3 or summation vitD after
age was included in the model.
Daily vitamin D intake was estimated for 74/100 cats. For the
remaining cats, insufficient information about specific food and flavor,
daily amount consumed, or the food's vitamin D content precluded
making reasonable estimates of vitamin D intake. The CM group did
have higher estimated vitamin D intake compared to the N group
(median = 22.6 IU/kg and 15.5 IU/kg, respectively; P = .002). How-
ever, no correlation was found between vitamin D intake and serum
25(OH)D3, 3-epi, or summation vitD for all cats in which data were
available. Neither was correlation found when CM and N cats were
tested separately.
4 | DISCUSSION
A striking finding in our study was the important effect of cat age on
vitamin D status, both for 25(OH)D3 alone and summation vitD, with
older cats more likely to have lower vitamin D status. To our knowl-
edge, this age influence on 25(OH)D and summation vitD has not
been reported previously in cats. In dogs with DMVD, although an
age difference was noted between control group and stage C or D
heart failure group, no correlation was found between 25(OH)D con-
centration and age.5 The other published study involving dogs with
clinical cardiac disease also found no significant association between
age and 25(OH)D.4 Although the CHF group was older than the con-
trols in that study, univariate linear regression of all dogs across both
F IGURE 2 Box plots with data points of serum 25(OH)D3
concentrations for CM and N cats. Box plots show comparison
between serum 25(OH)D3 concentrations for cats with CM and
normal cats. After accounting for age, the difference became
nonsignificant (P = .07). Bar inside each box indicates median, with
lower and upper edges marking 25th and 75th percentiles,
respectively. Mean values indicated by red diamonds. CM,
cardiomyopathy
F IGURE 3 Box plots with data points of summation vitamin D
concentrations for CM and N cats. Box plots show comparison
between summation vitamin D (serum 25(OH)D3 plus 3-epi-25(OH)
D3 concentrations) for cats with CM and normal cats. Difference is
significant, both before (P = .03) and after (P = .04) accounting for age.
Bar inside each box indicates median, with lower and upper edges
marking 25th and 75th percentiles, respectively. Mean values
indicated by red diamonds. CM, cardiomyopathy
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populations showed no significant relationship between age and 25
(OH)D concentration. Those investigators also found that multivari-
able regression analysis controlling for age indicated that the signifi-
cant difference in 25(OH)D concentration between groups was
maintained.4 Likewise, in another study of 69 dogs with cancer com-
pared to 23 healthy dogs, 25(OH)D concentration was lower in the
different cancer groups, but no age effect was identified on 25(OH)D
concentration.14 Studies in people have had conflicting findings. Given
comparable intake of vitamin D, some report no association between
age and 25(OH)D concentration.15,16 However, increased vitamin D
intake and sun exposure do lead to higher 25(OH)D concentrations. In
contrast, a study involving adults >60 years of age that focused on
the relationship of vitamin D status to antioxidant status did find that
median age was older in people with baseline 25(OH)D con-
centration < 50 nM/L (ie, <20 ng/mL) compared to those with higher
25(OH)D concentrations, although there was much overlap.17 Follow-
up measurement 8 years later within the same population identified a
significant decrease in median 25(OH)D, despite comparable dietary
vitamin D intake and percentage of individuals taking vitamin D
supplements.
In our study, the 3-epi metabolite was present in substantial
amounts in both CM and N cats, thus it appears to be an important
metabolite in this species. The fact that 3-epi alone, as well as the
ratio of 3-epi to summation vitD (or 3-epi as percentage of summation
vitD), was not different between CM and N cats suggests that forma-
tion of this metabolite is not affected by CM status. In our cat popula-
tion, 3-epi comprised a mean of almost 24% of summation vitD
concentration. In another study, a mean 3-epi concentration of
20.9 ng/mL (LC-MS method) was reported in a small group of adult
male cats, and 3-epi represented a mean of about 56% of 25(OH)D3
concentration.8 We found a smaller, but still substantial, concentration
of 3-epi in our larger and more diverse cat population. Expressed simi-
larly, our population's 3-epi concentration represented a mean of
33.2% of 25(OH)D3 concentration alone. The prior study also found
that increased dietary vitamin D intake led to an increase in serum 3-
epi concentration, but no significant change in 25(OH)D3.
8 Because
our study measured vitamin D metabolites at only 1 point in time, we
have no basis for comparison.
The concentration of the 3-epi metabolite in cats is much higher
and more consistently identified than that reported in people and
dogs. Although, 3-epi was identified in 87.2% of dogs sampled, con-
centrations were below the quantification limit in 40% of these and
median 3-epi concentration was only 5.2 nM/L (2.08 ng/mL).9 In peo-
ple, 3-epi was identifiable in variable proportions (0%-100%) of
populations studied and racial differences were found.18 In 1 study,
only 33% of Caucasians and 15% of African Americans had quantifi-
able (>1.4 ng/mL) 3-epi concentrations and these were low.7 Mean 3-
epi concentrations, when quantifiable, were 2.12 ng/mL and 2.16 ng/
mL in Caucasians and African Americans, respectively. Furthermore,
3-epi constituted only 3.23% and 2.25%, respectively, of the total of
25(OH)D3 and 3-epi concentrations (ie, summation vitD). An earlier
review of humans calculated a weighted mean across studies in adults,
estimating a median 3-epi of 1.72 ng/mL, with 3-epi constituting
approximately 6.1% of summation vitD.18 As in our study of cats, 3-
epi concentrations in people and dogs have correlated positively with
25(OH)D3 concentrations.
7,9
Given the concentrations of 3-epi in cats, we think it reasonable
to consider the sum of 3-epi and 25(OH)D3 concentrations as a
potential clinical index of vitamin D status in this species. Such an
approach also has been used in people7 and, in view of the higher cir-
culating 3-epi concentration in cats compared to people, this
approach seems especially relevant. Studies in rodents and in vitro
studies suggest that 3-epi and the epimeric form of calcitriol bind to
vitamin D binding protein at 36% to 46% of the affinity of the parent
molecules, and to vitamin D receptors at 2% to 3% of 25(OH)D and
calcitriol, respectively.7 The epimeric form of calcitriol was shown to
suppress parathyroid hormone secretion similarly to the nonepimeric
form, despite its lesser capacity to bind the vitamin D receptor.19
After accounting for age in our study, the difference in 25(OH)D3
concentration alone between CM and N groups was not statistically
significant. However, mean summation vitD was different between
CM and N cat groups, both before and after accounting for age. If
summation vitD is a better index of vitamin D status in cats, rather
than 25(OH)D3 alone, our findings are consistent with studies in peo-
ple and dogs, which identify lower vitamin D status associated with
serious CV disease.1-5
We found survival time to be associated with both summation
vitD and 25(OH)D3, even after accounting for age. However, we did
not observe actual survival days beyond the study's end date, meaning
this variable is right-censored. Admittedly, such a limitation could
cause bias in model estimation, which is another reason for removing
it in the final regression models for 25(OH)D3 and summation vitD.
Vitamin D status, assessed by 25(OH)D concentration, also was an
independent predictor of mortality in a study of 99 sick cats (with var-
ious disease conditions) when the analysis used 25(OH)D as a cate-
gorical value, although not as a continuous variable.20 In that study,
cats with 25(OH)D concentrations in the lowest tertile, <73.6 nM/L
(ie, <29.4 ng/mL), had higher mortality compared to cats with higher
25(OH)D concentrations, with an odds ratio of 8.27 for death within
30 days. In dogs with DMVD, a significant association between
25(OH)D concentration and time to clinical CHF signs or sudden
death was reported.4 Lower serum 25(OH)D concentrations also were
identified in dogs with chronic enteropathy with death related to their
disease.21 Multiple studies in people have shown an association
between vitamin D deficiency and increased incidence of all-cause, as
well as CV, mortality.1-3
Declining renal function is known to impair conversion of 25(OH)
D3 to the active 1,25 (OH2)D3 (calcitriol) in people.
15 This effect is
exacerbated when the supply of substrate (ie, 25(OH)D) is decreased.
Nevertheless, data analysis in our cats showed that azotemia status
was related to age and not to vitamin D status, whether assessed by
25(OH)D3 alone or by summation vitD.
Vitamin D exerts its effects mainly by activating vitamin D recep-
tors, which function as a transcription factor that regulates various
downstream signaling pathways and controls target gene transcription
and expression. Vitamin D receptors are expressed in many tissues,
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including the heart.1,6,22 Experimental studies in mice, rats, and swine
have shown vitamin D to have several cardioprotective effects,
including decreases in renin-angiotensin activation, myocardial hyper-
trophy, endothelial dysfunction, and pro-inflammatory cytokines.3,22-
24 Cardiac contractility and intracellular calcium dynamics also are
affected by cardiac vitamin D receptor activation.24 Systemically, ade-
quate vitamin D availability also helps decrease inflammation, improve
immunity, and could have antioxidant properties.6,14,17,25 Adequate
vitamin D concentrations have been associated with decreased occur-
rence of diabetes, CV disease, and certain cancers, among other con-
ditions in people. Vitamin D deficiency is thought to contribute to
sustained renin-angiotensin-aldosterone axis activation.2 Whether
vitamin D directly influences mortality or if other systemic effects of
low vitamin D status ultimately influence survival is unclear. Likewise,
changes in vitamin D status possibly may be secondary to various dis-
eases, rather than a primary cause of morbidity and mortality.
In people, serum 25(OH)D concentrations ≥30 ng/mL are consid-
ered sufficient (although possibly not optimal); 25(OH)D concentra-
tions of 20 to 29 ng/mL are considered insufficient, and <20 ng/mL is
considered deficient. Concentrations of 25(OH)D that correspond to
sufficient, insufficient (suboptimal), or deficient in cats are not well
defined. Previous studies in cats have found a wide range of serum 25
(OH)D concentrations in normal cats, with reported median concen-
trations between 44.7 and 49 ng/mL.6 The median 25(OH)D3 concen-
tration in our N group was slightly lower, at close to 43 ng/mL.
Measurement methodology can affect results. Additionally, the contri-
bution of 3-epi, if any, to determinations of vitamin D sufficiency in
cats is unclear.
Most studies of vitamin D status and heart failure in humans, and
the 2 reports in dogs, involve conditions likely to be associated with
decreased LV systolic function. However, cats with acquired cardiac
disease are more likely to have predominantly diastolic dysfunction.
Vitamin D is thought to have a protective effect in LV diastolic dys-
function, by inhibiting myocardial fibrosis and enhancing relaxation by
modulation of myocardial calcium mechanics.26 Conversely, an experi-
mental study in swine identified increased cardiomyocyte hypertro-
phy, as well as an increase in inflammatory markers in animals with
vitamin D deficiency.22 In cats with CM, the severity of LAE has been
viewed as a clinical indicator of LV diastolic dysfunction. Our study
showed a significant negative relationship between summation vitD
and LAE severity, even after accounting for age. Few reports of vita-
min D status are available in people with predominantly diastolic dys-
function. One study of middle-aged to older people with diastolic
dysfunction, but not specifically HCM, found that those with lower
25(OH)D concentrations had increased hospitalization rates, but only
a tendency (P = .05) for increased 5-year mortality.3 Patients in the
lowest tertile of 25(OH)D concentrations were older, more often
symptomatic, and had more severe LAE (calculated as LA volume
index) and higher NT-pro-brain natriuretic peptide concentrations.
Increased LA volume index, among other measures, was indepen-
dently associated with decreased 25(OH)D. Associations between a
higher probability of low 25(OH)D and measures of LV diastolic dys-
function, heart failure, and atrial fibrillation were found, even after
adjusting for age.3 Others have found a trend toward increased preva-
lence of diastolic dysfunction in patients with vitamin D deficiency.27
However, subsequent evaluation of that same patient cohort (asymp-
tomatic diastolic dysfunction or heart failure with preserved ejection
fraction) showed no strong association between 25(OH)D and myo-
cardial structure and function.28 We found no significant relationship
between LV hypertrophy and vitamin D status in our cats. However,
as an indicator of myocardial hypertrophy, our combined LV wall and
septal thickness measure was much less sensitive than histologic car-
diomyocyte examination.
Diagnosis category provided interesting results in our analysis of
summation VitD. The category other CM (consisting of cats with
RCM, DCM, and unspecified CM) showed lower mean summation
vitD compared to N cats, before age (as a continuous variable) was
included in the model. Although significance decreased with age
included, application of the age group filter showed that summation
vitD was lower in older (group 3) cats with the other CM classifica-
tion. This category included CM types generally considered to have
more advanced pathophysiology, involving either diastolic or systolic
dysfunction, or a combination. From this standpoint, the finding is
similar to reports of lower vitamin D status in people (and dogs) with
more advanced disease.
Calculation of FS (or ejection fraction) often is a clinical proxy for
LV systolic function. Our data showed FS was significantly related to
25(OH)D3 and summation vitD concentrations, even after accounting
for age. Decreased systolic function is likely in cats with RCM and
end-stage HCM, as well as in those with DCM. In people, worse vita-
min D status is more likely in those with advanced heart failure.
Most of our CM cats had experienced an episode of CHF at some
point in time. The majority of these had evidence for congestion (either
pulmonary edema or pleural effusion) at the time of study entry. Based
on studies in people and dogs with heart failure, we expected to find
lower vitamin D status in these cats. We found no association between
heart failure status and 25(OH)D3. A negative relationship between sum-
mation vitD and heart failure severity was detected before accounting
for age but, after including age in the model, the significance became only
borderline. Presumably, older cats are more likely to develop CHF, as well
as to have lower vitamin D status, and thus age as a confounder could be
responsible for the change in significance.
Our study had several limitations. One limitation is that we were
not able to control dietary intake of vitamin D in our cats. An entry
criterion was that the primary diet be a commercially available diet,
for which vitamin D content should be available from the manufac-
turers. However, it was not possible to quantitate the exact amounts
of different foods (and flavors) eaten daily by each cat and not all
manufacturers were able to supply vitamin D information. There-
fore, the estimation of dietary vitamin D intake was incomplete.
Besides variability in the types of food fed, some cats had free-
choice access, often with other cats in the household, so their food
intake could not be accurately quantified. Furthermore, we could
not quantitate vitamin D intake from table food, cat treats, or other
foods that might have been given to (or found by) the cats, although
these comprised only a minor proportion of the diet in this
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population. In addition, because we sampled these cats at only 1
time point, we have no way of knowing whether changes in vitamin
D concentration over time might occur relative to disease progres-
sion or dietary change in CM cats. Likewise, we do not know if PO
vitamin D supplementation would affect disease progression or
survival.
Given the substantial circulating concentrations of 3-epi in
cats, we suspect that summation vitD could be a better index of
vitamin D status in this species, compared to 25(OH)D3 alone.
However, further study is needed to determine if this truly is the
case. The most biologically active form of vitamin D is calcitriol (1,
25 (OH2)D3), which we did not measure. Likewise, we did not
attempt to measure the epimer of calcitriol, which experimental
studies have indicated has some biological effect. Additional
research will be important to clarify the effects and relationships
among these vitamin D metabolites in cats.
In conclusion, we report on 25(OH)D3 and its C-3 epimer (3-epi)
concentrations in cats with CM and in clinically healthy cats. Notable
concentrations of 3-epi are present in this species, in contrast to the
situation in people and dogs. Therefore, 3-epi could contribute impor-
tantly to the clinical assessment of total vitamin D status in cats. In
addition, we found that age had a significant negative effect on vita-
min D status, whether assessed by 25(OH)D3 alone or by the sum of
25(OH)D3 and 3-epi concentrations (ie, summation vitD). After
accounting for age, summation vitD was lower in CM compared to N
cats. Vitamin D status also was positively related to survival time and
FS, but negatively related to LAE severity.
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